Multilineage human wound skinoid platform for compound screening
Columbia University introduces a 3D human wound skinoid platform that replicates all wound healing phases, enabling efficient compound screening with pheno-transcriptomic fidelity. This scalable solution offers new insights into keratinocyte-fibroblast interactions, critical for healing research.
Overview
Columbia University presents a groundbreaking multilineage human wound skinoid platform designed for advanced compound screening and wound healing research. This innovative platform replicates the complete wound healing process, providing pheno-transcriptomic readouts that closely mimic in vivo conditions. Developed by the Woappi Lab, these skinoids effectively capture the complex interactions between keratinocytes and fibroblasts, addressing limitations of traditional 2D assays and animal models. This platform is poised to transform pharmacological research, particularly in chronic and impaired wound healing, a field impacting millions of surgeries and chronic conditions annually.
Technical specifications
- 3D organoid model: Combines primary keratinocytes and fibroblasts to mimic human skin wound healing phases: hemostasis, inflammation, proliferation, and remodeling.
- Standard formats: Available in 6-, 12-, 24-, and 96-well plates for scalable, reproducible workflows.
- Advanced readouts: Utilizes H&E imaging and RNA sequencing, benchmarked against a comprehensive single-cell wound atlas.
- Scalability: Compatible with lab automation and standard compound libraries, enhancing throughput and efficiency.
Technology readiness level
The platform is at Technology Readiness Level 5, indicating it has undergone validation under relevant conditions. Future phases involve optimization for compound screening, pilot testing with partner libraries, and scaling for larger deployments, ensuring robust, real-world application.
About Columbia University
Columbia University is a comprehensive private research university in New York City, combining an Ivy League academic profile with globally engaged scholarship and professional education. Its integration with a major hospital system through Columbia University Irving Medical Center and NewYork-Presbyterian enables clinical collaboration, access to diverse patient populations, and regulated studies at scale. State-of-the-art laboratories and shared core facilities across the Morningside and Manhattanville campuses support co-located industry projects, while proximity to New York’s finance, media, and healthcare ecosystems streamlines talent pipelines and pilot deployments. Industry engages via sponsored research, affiliate programs, executive education, and convenings that connect faculty expertise with corporate R&D priorities. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD, alongside New York State and philanthropic sources. Columbia Technology Ventures provides IP management, licensing, startup support, and translational funding mechanisms that lower barriers to commercialization.
delivered to your inbox.